Kuchyne na miru

Value Based Care Predicted as Macro Driver for 2019 Trends

Jan 09, 2019

In 2019, the pharma industry will need to deliver on the talk of the past few years. Technology visionaries and forecasters have been warning that the pharmaceutical industry should be engaging patients on their treatments and capturing real world patient data as part of their services and product offerings to stay competitive in a changing healthcare landscape and meet the demands of Value Based Care. Next year, pharma firms will finally have to make that move, or risk being left behind.

The top 5 trends for 2019 will be driven by Value Based Care

1.       Realtime RWD

2.       Digital Therapeutics (DTx)

3.       Scalable and Personalized Patient Support Services

4.       AI Comes of Age

5.       Medicine-as-a-Service


With increasingly constrained healthcare budgets, providers and payers want to understand the value they get from the money they spend on drugs and other therapies. With the move to value-based contracts, expect to represent a growing margin of healthcare spend by 2020, the winning firms will be those that can demonstrate value which will be powered by real world data.

At the heart of the movement towards Value Based Care is a clear focus on outcomes. The toolbox the industry can use to influence outcomes is growing to include digitally enhanced patient services and digital therapeutics (DTx), that have the ability to capture real world data, evidence of engagement, adherence, and outcomes.

In 2019, the capture of real world data will become a baseline requirement for any patient services launched to market. These services will have to be scalable and personalized to each patient’s individual needs, helping patients understand and manage their treatment, while also monitoring improvements in healthcare outcomes and quality of life. Armed with this data, pharma firms can also meet payers’ and providers’ growing demands to demonstrate value and access reimbursement through value-based contracts.

But data will not only help the pharma industry access reimbursement. Real-world data will propel the growth of AI in Healthcare to deliver new solutions that will improve speed and accuracy of medical diagnosis, power research and development of new treatments and drug discovery, and enable process efficiencies in the delivery of care.

Winners in the market will provide software to offer behavioral interventions that support patients’ individual needs with treatments. New drug launches will include wrap-around technology-enabled services that focus on the patient experience and ensure patients achieve the best outcomes possible from the therapy, through adherence and lifestyle changes. Digitally-led therapeutics will increasingly support, improve, augment, or event replace current single modality/pharmaceutical treatments.

The combined offer of therapies and digital services will be standardized over multiple territories with personalized support and real-time interventions based on patients’ real-world challenges. Healthcare payers and providers will begin to specify these approaches in RFPs as the pharma industry looks to a future beyond the provision or a product or pill and moves to providing medicine-as-a-service, a concept which will continue to gain momentum well beyond 2019.


Jim O'Donoghue, President of S3 Connected Health.





lorem ipsum